Dynamic quotes: Off
|
Company Description (as filed with the SEC)
All references to “we,” “our,” and “us” in this Annual Report refer to Quidel Corporation and its subsidiaries. Overview We have a leadership position in the development, manufacturing and marketing of rapid diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. We sell our products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics and wellness screening centers. We market our products in the United States through a network of national and regional distributors, and a direct sales force. Internationally, we sell and market primarily in Japan and Europe through distributor arrangements. We commenced our operations in 1979 and launched our first products, dipstick-based pregnancy tests, in 1983. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0.37 |
| Quarterly EPS Est: | -0.08 |
| PEG Ratio: | 3.39 |
|
Mean Recommendation: View Summary / View All |
2.18 |
Data is provided by Zacks Investment Research
